Kim Tae Hee, Kang Doo Kyoung, Yim Hyunee, Jung Yong Sik, Kim Ku Sang, Kang Seok Yun
Department of Radiology, Gyeonggi-do, South Korea.
J Comput Assist Tomogr. 2012 Mar-Apr;36(2):200-6. doi: 10.1097/RCT.0b013e318246abf3.
The objectives of the study were to analyze the tumor shrinkage pattern on magnetic resonance imaging (MRI) after neoadjuvant chemotherapy and to evaluate whether there is any difference in shrinkage pattern between pathological responder and nonresponder groups. In addition, we wanted to compare tumor diameter obtained from MRI with histological diameter according to the tumor shrinkage pattern.
Between July 2008 and December 2010, 55 consecutive patients (56 lesions) with pathologically proven breast cancer who underwent neoadjuvant chemotherapy followed by surgery were retrospectively enrolled. The shrinkage pattern was classified into 4 categories: I (concentric shrinkage without surrounding lesion), II (concentric shrinkage with surrounding lesions), III (shrinkage with residual multinodular lesions, and IV (diffuse contrast enhancement in whole quadrants). Histological regression was scored on a 5-point scale regarding tumor cellularity reduction (Miller-Payne grading system). Patients with Miller-Payne grade 1 or 2 were classified into the nonresponder group, and patients with grade 3, 4, or 5 were in the responder group.
Of 56 lesions, pattern I was seen in 29 lesions, pattern II in 13 lesions, pattern III in 5 lesions, and pattern IV in 4 lesions. Three lesions were not visualized on MRI after neoadjuvant chemotherapy, and 2 lesions were increased in size. There was a statistically significant difference in the tumor shrinkage pattern between responder and nonresponder groups (P = 0.017). All 5 lesions with type III shrinkage pattern were found in the responder group, and all 4 lesions with pattern IV were in the nonresponder group. Magnetic resonance imaging diameter of lesions with types I, II, and IV patterns showed significant correlation with the histological diameter. Among them, the correlation factor was highest in pattern IV (ρ = 0.94, P < 0.001) followed by pattern I (ρ = 0.67, P < 0.01) and pattern II (ρ = 0.502, P = 0.08). However, in type III shrinkage pattern, tumor size measured on MRI was not significantly correlated with histological size (P = 0.87).
Types III and I shrinkage patterns were more frequently observed in the pathological responder group, and type IV was more frequently noted in the nonresponder group. Tumor diameter measured on MRI showed strong correlation with histological diameter in lesions with types I and IV shrinkage patterns, whereas lesions with type III did not show significant correlation. Type II pattern showed similar frequencies between the 2 groups and moderate correlation between sizes obtained from MRI and histology.
本研究的目的是分析新辅助化疗后磁共振成像(MRI)上的肿瘤缩小模式,并评估病理反应者和无反应者组之间的缩小模式是否存在差异。此外,我们想根据肿瘤缩小模式比较MRI获得的肿瘤直径与组织学直径。
回顾性纳入2008年7月至2010年12月期间连续55例(56个病灶)经病理证实的乳腺癌患者,这些患者接受了新辅助化疗后进行手术。缩小模式分为4类:I(同心缩小无周围病变),II(同心缩小有周围病变),III(缩小有残留多结节病变),IV(整个象限弥漫性对比增强)。根据肿瘤细胞减少情况(米勒-佩恩分级系统)对组织学消退进行5分制评分。米勒-佩恩1级或2级的患者分为无反应者组,3级、4级或5级的患者为反应者组。
56个病灶中,I型见于29个病灶,II型见于13个病灶,III型见于5个病灶,IV型见于4个病灶。新辅助化疗后3个病灶在MRI上未显示,2个病灶大小增加。反应者组和无反应者组之间的肿瘤缩小模式存在统计学显著差异(P = 0.017)。所有5个III型缩小模式的病灶均在反应者组中发现,所有4个IV型病灶均在无反应者组中。I型、II型和IV型模式病灶的MRI直径与组织学直径显示出显著相关性。其中,IV型的相关系数最高(ρ = 0.94,P < 0.001),其次是I型(ρ = 0.67,P < 0.01)和II型(ρ = 0.502,P = 0.08)。然而,在III型缩小模式中,MRI测量的肿瘤大小与组织学大小无显著相关性(P = 0.87)。
III型和I型缩小模式在病理反应者组中更常见,IV型在无反应者组中更常见。MRI测量的肿瘤直径与I型和IV型缩小模式病灶的组织学直径显示出强相关性,而III型病灶未显示出显著相关性。II型模式在两组中的频率相似,且MRI和组织学获得的大小之间存在中度相关性。